Gilead Hikes Profit Outlook As Biggest HIV Drug Outperforms Expectations
Gilead stock was muted late Thursday despite reporting strong sales from its bread-and-butter HIV treatment, Biktarvy, and its cell therapies. The post Gilead Hikes Profit Outlook As Biggest HIV Drug Outperforms Expectations appeared first on Investor's Business Daily.
Gilead stock was muted late Thursday despite reporting strong sales from its bread-and-butter HIV treatment, Biktarvy, and its cell therapies.
The post Gilead Hikes Profit Outlook As Biggest HIV Drug Outperforms Expectations appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
